Delving into the Latest Updates on Organon GmbH with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

激素	1
小分子化药	1

排名前五的靶点	数量

PR(孕激素受体)	1
FSHR(卵泡刺激素受体)	1

关联

2

项与 Organon GmbH 相关的药物

Desogestrel

去氧孕烯

靶点

PR

作用机制

PR激动剂

在研机构

Organon GmbH

原研机构

Organon GmbH

在研适应症

避孕

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

瑞士

首次获批日期2000-03-28

Follitropin Beta

重组促卵泡素β

靶点

FSHR

作用机制

FSHR激动剂

在研机构

Organon NV [+4]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

无排卵 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期1996-05-02

1

项与 Organon GmbH 相关的临床试验

NCT00805662 / CompletedN/AIIT

Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI

Placebo-controlled study. Application of nasal oxytocin (8 IU) during intrauterine insemination in 86 patients.

开始日期2003-05-01

申办/合作机构

Ludwig-Maximilians-Universität München

[+2]

100 项与 Organon GmbH 相关的临床结果

登录后查看更多信息

0 项与 Organon GmbH 相关的专利（医药）

登录后查看更多信息

3

项与 Organon GmbH 相关的文献（医药）

2022-12-01·BMC Health Services Research

Use of algorithms for identifying patients in a German claims database: learnings from a lung cancer case

Article

作者: Chruscz, Detlef ; Neugebauer, Sina ; Heidenreich, Stephanie ; Dippel, Sabine ; Kaskel, Peter ; Lempfert, Sebastian ; Griesinger, Frank ; Gruber, Nina

AbstractBackgroundThe analysis of statutory health insurance (SHI) data is a little-used approach for understanding treatment and care as well as resource use of lung cancer (LC) patients in Germany. The aims of this observational, retrospective, longitudinal analysis of structured data were to analyze the healthcare situation of LC patients in Germany based on routine data from SHI funds, to develop an algorithm that sheds light on LC types (non-small cell / NSCLC vs. small cell / SCLC), and to gain new knowledge to improve needs-based care.MethodsAnonymized billing data of approximately four million people with SHI were analyzed regarding ICD-10 (German modification), documented medical interventions based on the outpatient SHI Uniform Assessment Standard Tariff (EBM) or the inpatient Operations and Procedure Code (OPS), and the dispensing of prescription drugs to outpatients (ATC classification). The study included patients who were members of 64 SHI funds between Jan-1st, 2015 and Dec-31st, 2016 and who received the initial diagnosis of LC in 2015 and 2016.ResultsThe analysis shows that neither the cancer type nor the cancer stage can be unambiguously described by the ICD-10 coding. Furthermore, an assignment based on the prescribed medication provides only limited information: many of the drugs are either approved for both LC types or are used off-label, making it difficult to assign them to a specific LC type. Overall, 25% of the LC patients were unambiguously identifiable as NSCLC vs SCLC based on the ICD-10 code, the drug therapy, and the billing data.ConclusionsThe current coding system appears to be of limited suitability for drawing conclusions about LC and therefore the SHI patient population. This makes it difficult to analyze the healthcare data with the aim of gathering new knowledge to improve needs-based care. The approach chosen for this study did not allow for development of a LC differentiation algorithm based on the available healthcare data. However, a better overview of patient specific needs could make it possible to modify the range of services provided by the SHI funds. From this perspective, it makes sense, in a first step, to refine the ICD-10 system to facilitate NSCLC vs. SCLC classification.

1990-12-01·Therapeutische Umschau. Revue therapeutique

Hat die Pille eine psychotrope Wirkung?

Article

作者: Geissler, K H

Like for other side effects oral contraceptives are often blamed for inducing depressive illness. Psychiatric literature and own data permit the following statements: 1. OC's do not induce psychiatric symptoms like depression on a pharmacological basis. 2. There is no preponderance of psychiatric symptoms during pill use. 3. If there is any effect on mood, initiative or affection this is more likely to be mentioned in patients with psychiatric history. 4. The indication for oral contraception in neurotic-psychopathic personalities should be considered seriously. 5. There is a positive secondary psychotropic effect of OC's via improving acne, bleeding irregularities and dysmenorrhoea.

Arzneimittelforschung

Local Treatment of Vaginal Infections of Varying Etiology with Dequalinium Chloride or Povidone Iodine

Article

作者: Spitzbart, Heinz ; Weissenbacher, Ernst ; Wolfgang, Weise ; Dreher, Ekkehard ; Ernst, Uwe ; Hengst, Peter ; Wolff, Friedrich ; Kaiser, R. ; Petersen, Eiko ; Casa, Vera ; Pohlig, Gabriele ; Graf, Federico

This randomised, double-blind, multicentric clinical study compared the efficacy and tolerability of the two vaginal antiseptics, 10 mg dequalinium chloride (CAS 522-51-0, Fluomycin N) and 200 mg povidone iodine (CAS 25655-41-8), in a parallel-group design. A total of 180 patients with vaginal infections of varying etiology participated in this study (bacterial vaginosis, fluor vaginalis, vulvo-vaginal candidiasis, trichomoniasis). Patients were randomly allocated to one of the two treatment groups and were treated once per day for 6 days. Control examinations took place 5 to 7 days after the end of treatment, and 3 to 4 weeks after the first control examination. The total symptoms score, a summary score for the clinical symptoms, discharge, burning, pruritus, redness of vulva/vagina, was defined as primary efficacy parameter. The treatments at the first control examination were compared in the full analysis set using the Wilcoxon-Mann-Whitney U-test, 2-sided, thereby proving equivalence of both treatments at the 5% level. Both treatments strongly improved the symptoms of vaginal infections both on short-term and long-term follow-up. Descriptive analysis of the secondary parameters, vaginal pH, degree of purity of the vaginal flora, and number of lactobacilli in the wet mounts, supported the comparable efficacy of both therapies to restore the vaginal milieu. Analysis of the diagnostic subgroups indicated that irrespective of the diagnosis, both treatments improved the efficacy criteria as observed for the entire population. The global assessment of the therapeutic efficacy by investigators and patients supported the results of the efficacy analysis with good to very good ratings in 70-90% of the cases. A good tolerability of both preparations was observed in this study with a low number of adverse events in the test group (5.8%).

100 项与 Organon GmbH 相关的药物交易

登录后查看更多信息

100 项与 Organon GmbH 相关的转化医学

登录后查看更多信息